An Update on Osteogenesis Imperfecta

Roland Kocijan, Christian Muschitz, Judith Haschka, Heinrich Resch



Full Text:



Monti E., Mottes M., Fraschini P., Brunelli P., Forlino A., Venturi G., Doro F., Perlini S., Cavarzere P., Antoniazzi F. Current and emerging treatments for the management of osteogenesis imperfecta // Ther. Clin. Risk Manag. — 2010. — 6:367-81.

Sillence D.O., Senn A., Danks D.M. Genetic heterogeneity in osteogenesis imperfecta // J. Med. Genet. — 1979. — 16(2). — 101-16.

Willing M.C., Pruchno C.J., Byers P.H. Molecular heterogeneity in osteogenesis imperfecta type I // Am. J. Med. Genet. — 1993. — 45(2). — 223-7.

Forlino A., Cabral W.A., Barnes A.M., Marini J.C. New perspectives on osteogenesis imperfecta // Nat. Rev. Endocrinol. — 2011. — 7(9). — 540-57.

Marini J.C., Cabral W.A., Barnes A.M., Chang W. Components of the collagen prolyl 3-hydroxylation complex are crucial for normal bone development // Cell Cycle. — 2007. — 6(14). — 1675-81.

Barnes A.M., Chang W., Morello R., Cabral W.A., Weis M., Eyre D.R., Leikin S., Makareeva E., Kuznetsova N., Uveges T.E., Ashok A., Flor A.W., Mulvihill J.J., Wilson Р.L., Sundaram U.T., Lee B., Marini J.C. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta // N. Engl. J. Med. — 2006. — 355(26). — 2757-64.

Morello R., Bertin T.K., Chen Y., Hicks J., Tonachini L., Monticone M., Castagnola P., Rauch F., Glorieux F.H., Vranka J., Bachinger H.P., Pace J.M., Schwarze U., Byers P.H., Weis M., Fernandes R.J., Eyre D.R., Yao Z., Boyce B.F., Lee B. CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta // Cell. — 2006. — 127(2). — 291-304.

Cohn D.H., Starman B.J., Blumberg B., Byers P.H. Recurrence of lethal osteogenesis imperfecta due to parental mosaicism for a dominant mutation in a human type I collagen gene (COL1A1) // Am. J. Hum. Genet. — 1990. — 46(3). — 591-601.

Cabral W.A., Chang W., Barnes A.M., Weis M., Scott M.A, Leikin S., Makareeva E., Kuznetsova N.V., Rosenbaum K.N., Tifft C.J., Bulas D.I., Kozma C., Smith P.A., Eyre D.R., Marini J.C. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta // Nat. Genet. — 2007. — 39(3). — 359-65.

Wekre L.L., Eriksen E.F., Falch J.A. Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta // Arch. Osteoporos. — 6(1—2). — 31-8.

Glorieux F.H., Rauch F., Plotkin H., Ward L., Travers R., Roughley P., Lalic L., Glorieux D.F., Fassier F., Bishop N.J. Type V osteogenesis imperfecta: a new form of brittle bone disease // J. Bone Miner. Res. — 2000. — 15(9). — 1650-8.

Glorieux F.H., Ward L.M., Rauch F., Lalic L., Roughley P.J., Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect // J. Bone Miner. Res. — 2002. — 17(1). — 30-8.

Semler O., Netzer C., Hoyer-Kuhn H., Becker J., Eysel P., Schoenau E. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI // J. Musculoskelet Neuronal Inte­ract. — 2012. — 12(3). — 183-8.

Ward L.M., Rauch F., Travers R., Chabot G., Azouz E.M., Lalic L., Roughley P.J., Glorieux F.H. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease // Bone. — 2002. — 31(1). — 12-8.

Goldman A.B., Davidson D., Pavlov H., Bullough P.G. Popcorn calcifications: a prognostic sign in osteogenesis imperfecta // Radiology. — 1980. — 136(2). — 351-8.

Charnas L.R., Marini J.C. Communicating hydrocephalus, basilar invagination, and other neurologic features in osteogenesis imperfecta // Neurology. — 1993. — 43(12). — 2603-8.

Braga V., Gatti D., Rossini M., Colapietro F., Battaglia E., Viapiana O., Adami S. Bone turnover markers in patients with osteogenesis imperfecta // Bone. — 2004. — 34(6). — 1013-6.

Cepollaro C., Gonnelli S., Pondrelli C., Montagnani A., Martini S., Bruni D., Gennari C. Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters // Calcif. Tissue Int. — 1999. — 65(2). — 129-32.

Marini J.C., Bordenick S., Heavner G., Rose S., Hintz R.,

Rosenfeld R., Chrousos G.P. The growth hormone and somatomedin axis in short children with osteogenesis imperfecta // J. Clin. Endocrinol. Metab. — 1993. — 76(1). — 251-6.

Garnero P., Schott A.M., Prockop D., Chevrel G. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations // Bone. — 2009. — 44(3). — 461-6.

Cundy T., Horne A., Bolland M., Gamble G., Davidson J. Bone formation markers in adults with mild osteogenesis imperfecta // Clin. Chem. — 2007. — 53(6). — 1109-14.

Rauch F., Travers R., Parfitt A.M., Glorieux F.H. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta // Bone. — 2000. — 26(6). — 581-9.

Weber M., Roschger P., Fratzl-Zelman N., Schoberl T., Rauch F., Glorieux F.H., Fratzl P., Klaushofer K. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta // Bone. — 2006. — 39(3). — 616-22.

Rauch F., Plotkin H., Zeitlin L., Glorieux F.H. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy // J. Bone Miner. Res. — 2003. — 18(4). — 610-4.

Lindahl K., Barnes A.M., Fratzl-Zelman N., Whyte M.P., Hefferan T.E., Makareeva E., Brusel M., Yaszemski M.J., Rubin C.J., Kindmark A., Roschger P., Klaushofer K., McAlister W.H., Mumm S., Leikin S., Kessler E., Boskey A.L., Ljunggren O., Marini J.C. COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfect // Hum. Mutat. — 2011. — 32(6). — 598-609.

Kocijan R., Muschitz C., Fratzl-Zelman N., Haschka J., Dimai H.P., Trubrich A., Bittighofer C., Resch H. Femoral geometric parameters and BMD measurements by DXA in adult patients with different types of osteogenesis imperfecta // Skeletal Radiol. — 2012.

Folkestad L., Hald J.D., Hansen S., Gram J., Langdahl B., Abrahamsen B., Brixen K. Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT // J. Bone Miner. Res. — 2012. — 27(6). — 1405-12.

Marini J.C., Hopkins E., Glorieux F.H., Chrousos G.P., Reynolds J.C., Gundberg C.M., Reing C.M. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen // J. Bone Miner. Res. — 2003. — 18(2). — 237-43.

Antoniazzi F., Bertoldo F., Mottes M., Valli M., Sirpresi S., Zamboni G., Valentini R., Tato L. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis // J. Pediatr. — 1996. — 129(3). — 432-9.

Marini J.C., Bordenick S., Heavner G., Rose S., Chrousos G.P. Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta // Am. J. Med. Genet. — 1993. — 45(2). — 261-4.

Sakkers R., Kok D., Engelbert R., van Dongen A., Jansen M., Pruijs H., Verbout A., Schweitzer D., Uiterwaal C. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study // Lancet. — 2004. — 363(9419). — 1427-31.

Gatti D., Antoniazzi F., Prizzi R., Braga V., Rossini M., Tato L., Viapiana O., Adami S. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study // J. Bone Miner. Res. — 2005. — 20(5). — 758-63.

Letocha A.D., Cintas H.L., Troendle J.F., Reynolds J.C., Cann C.E., Chernoff E.J., Hill S.C., Gerber L.H., Marini J.C. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement // J. Bone Miner. Res. — 2005. — 20(6). — 977-86.

Uveges T.E., Kozloff K.M., Ty J.M., Ledgard F., Raggio C.L., Gronowicz G., Goldstein S.A., Marini J.C. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation // J. Bone Miner. Res. — 2009. — 24(5). — 849-59.

Glorieux F.H., Bishop N.J., Plotkin H., Chabot G., Lanoue G., Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta // N. Engl. J. Med. — 1998. — 339(14). — 947-52.

Brown J.J., Zacharin M.R. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis // J. Pediatr. Endocrinol. Metab. — 2009. — 22(1). — 55-63.

Panigrahi I., Das R.R., Sharda S., Marwaha R.K., Khandelwal N. Response to zolendronic acid in children with type III osteogenesis imperfecta // J. Bone Miner. Metab. — 2010. — 28(4). — 451-5.

Bradbury L.A., Barlow S., Geoghegan F., Hannon R.A., Stuckey S.L., Wass J.A., Russell R.G., Brown M.A., Duncan E.L. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists // Osteoporos Int. — 2012. — 23(1). — 285-94.

Papapoulos S.E., Cremers S.C. Prolonged bisphosphonate release after treatment in children // N. Engl. J. Med. — 2007. — 356(10). — 1075-6.

Whyte M.P., Wenkert D., Clements K.L., McAlister W.H., Mumm S. Bisphosphonate-induced osteopetrosis // N. Engl. J. Med. — 2003. — 349(5). — 457-63.

Munns C.F., Rauch F., Zeitlin L., Fassier F., Glorieux F.H. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate // J. Bone Miner. Res. — 2004. — 19(11). — 1779-86.

Muschitz C., Fahrleitner-Pammer A., Huber J., Preisin­ger E., Kudlacek S., Resch H. Update on denosumab in postmenopausal osteoporosis-recent clinical data // Wien Med. Wochenschr. — 2012. — 162(17–18). — 374-379.

Yuasa T., Yamamoto S., Urakami S., Fukui I., Yonese J. Denosumab: a new option in the treatment of bone metastases from urological cancers // Onco Targets. Ther. — 2012. — 5. — 221-9.

Johnson B.E. Review: Teriparatide reduces fractures in postmenopausal women with osteoporosis // Ann. Intern. Med. — 2012. — 157(6). — JC3-4.

Li X., Ominsky M.S., Warmington K.S., Morony S., Gong J., Cao J., Gao Y., Shalhoub V., Tipton B., Haldankar R., Chen Q., Winters A., Boone T., Geng Z., Niu Q.T., Ke H.Z., Kostenuik P.J., Simonet W.S., Lacey D.L., Paszty C. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis // J. Bone Miner. Res. — 2009. — 24(4). — 578-88.

Sinder B.P., Eddy M.M., Ominsky M.S., Caird M.S., Marini J.C., Kozloff K.M. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta // J. Bone Miner. Res. — 2012.

Horwitz E.M., Prockop D.J., Fitzpatrick L.A., Koo W.W., Gordon P.L., Neel M., Sussman M., Orchard P., Marx J.C., Pyeritz R.E., Brenner M.K. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta // Nat. Med. — 1999. — 5(3). — 309-13.

Wong R.S. Mesenchymal stem cells: angels or demons? // J. Biomed. Biotechnol. — 2011. — 459-510.

Binder H., Conway A., Hason S., Gerber L.H., Marini J., Berry R., Weintrob J. Comprehensive rehabilitation of the child with osteogenesis imperfecta // Am. J. Med. Genet. — 1993. — 45(2). — 265-9.

Gerber L.H., Binder H., Weintrob J., Grange D.K., Shapiro J., Fromherz W., Berry R., Conway A., Nason S., Marini J. Rehabilitation of children and infants with osteogenesis imperfecta. A program for ambulation // Clin. Orthop. Relat. Res. — 1990. — 251. — 254-62.

Zionts L.Е., Ebramzadeh E., Stott N.S. Complications in the use of the Bailey-Dubow extensible nail // Clin. Orthop. Relat. Res. — 1998. — 348. — 186-95.



  • There are currently no refbacks.

Copyright (c) 2016 PAIN. JOINTS. SPINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2017


 Яндекс.МетрикаSeo анализ сайта Рейтинг